LSL PHARMA GROUP PROVIDES UPDATE ON STERI-MED PRODUCTION AND SIGNS AGREEMENTS FOR SEVEN OPHTHALMIC PRODUCTS

Tuesday at 8:25am AST · November 17, 2026 6 min read

LSL PHARMA GROUP INC.  Logo

The Corporation also announces the addition of a new private–label product for a national customer.

BOUCHERVILLE, QC, Nov. 17, 2026 /CNW/ — LSL PHARMA GROUP INC. (TSXV: LSL) (the “Corporation” or “LSL Pharma”), a Canadian integrated pharmaceutical company, dedicated to improving human health and wellness with a stable contract manufacturing business and a high growth generic ophthalmic portfolio, is pleased to provide an update on its market opportunities and operations to enhance long-term shareholder value. 

Steri-Med Expected to Resume Production

Following the implementation of the key elements of a comprehensive remediation plan approved by Health Canada, Steri-Med’s production is expected to resume by the end of November. An earlier inventory buildup enabled an uninterrupted supply to the Corporation’s clients since the beginning of the fiscal year, including throughout the third quarter. As part of the business strategy, the Corporation plans to launch multiple ophthalmic generics in Canada and the US through 2030.

Adding Seven Sterile Ophthalmic Products 

As part of the LSL Pharma’s pipeline buildout, the Corporation signed in-licensing agreements adding seven sterile ophthalmic products to its portfolio. According to IQVIA Canadai, the Canadian market for these seven products represents more than C$95 million in annual sales. Commercialization remains subject to obtaining the necessary Health Canada approvals, and the Corporation expects to submit the related regulatory filings in the first quarter of 2027. The in-licensing agreements grant exclusive commercialization rights for periods ranging from five to seven years, with renewal options.

“On the eye-care side of the business, we are pleased that Steri-Med’s commercial production is expected to resume by the end of November, with Health Canada expected to visit shortly to assess our remediation plan’s implementation. The comprehensive remediation work completed at the facility will strengthen its quality systems and manufacturing capabilities, providing a stronger foundation for future growth. In addition, we have expanded our portfolio with seven ophthalmic products targeting Canadian market segments with combined annual sales exceeding C$95 million. These growth opportunities, combined with the attractive margin profile of our eye-care business, position us well for the years ahead,” said François Roberge, President and CEO

New private-label product for a National Customer

To advance our strategic growth objectives, LSL MedPlus entered into an agreement with a national customer and expects to begin supplying the private-label product in the first quarter of 2027. Based on the framework of the agreement with the customer, this product could make a significant contribution to the Private Label segment.

“The agreement with a national private-label client represents a significant milestone and could create similar opportunities in the future. Following a series of acquisitions that have driven substantial top-line growth, our focus on operational excellence and cross-selling initiatives is beginning to deliver measurable results,” concluded Mr. Roberge.

About LSL Pharma Group Inc.

LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceutical products, as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid dosage forms. Leveraging its technical expertise, certified facilities, and experienced team, LSL Pharma delivers high-quality solutions that meet the highest industry standards. The wholly-owned subsidiaries of LSL Pharma include Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Santé Inc., Dermolab Pharma Ltd., Laboratoire Du-Var Inc. and LSL MedPlus Inc. (formerly Juno OTC Inc.). For more information, please visit our website at at www.groupelslpharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable Canadian securities legislation, including, without limitation, statements regarding the expected commercialization of the seven ophthalmic products in Canada and the timing of related Health Canada approvals, the size of and competition in the targeted market segments, the expected start of supply under the private-label agreement in the first quarter of 2027, and the anticipated annual sales from the private-label product. Forward-looking statements include estimates and statements that describe the Corporation’s future plans, objectives or goals, including words to the effect that the Corporation or management expects a stated condition, belief, estimate or opinion, or result to occur. Forward-looking statements may be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “believe”, “aim”, “plan” “continue” or similar expressions. Forward-looking statements are based on a number of assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that could cause actual results or performance to differ materially from those expressed or implied in such forward-looking statements. Material assumptions underlying these forward-looking statements include that the required Health Canada approvals will be obtained on a timely basis; that the licensors will perform their obligations under the agreements; that the customer’s order volumes will be consistent with its current forecasts; and that the Corporation will be able to manufacture and supply the products on a cost-effective basis. These risks and uncertainties include, but are not limited to, delays in obtaining, or failure to obtain, regulatory approvals; the performance by the licensors and the customer of their obligations, and the risk that the agreements may be terminated; competition and pricing pressure; manufacturing, supply-chain and quality risks; changes in market conditions; and the other risk factors described in the Corporation’s continuous disclosure documents available on SEDAR+ at www.sedarplus.ca.

Financial Outlook. The anticipated annual sales from the private-label product described in this press release constitute a financial outlook within the meaning of applicable securities legislation. This financial outlook was approved by management as of the date of this press release and is provided to give readers information about management’s current expectations regarding the potential contribution of the private-label agreement to the Corporation’s sales. Readers are cautioned that this information may not be appropriate for other purposes. The financial outlook is based on the assumptions, and is subject to the risks and uncertainties, described above. Actual results may vary from the financial outlook, and the variations may be material.

Readers are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. The Corporation does not undertake to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

_______________________

i
 IQVIA Canada data for the 12-month period ended June 2026.

SOURCE Groupe LSL PHARMA INC.

displaying rededs